Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report. (2020)

• Record Type: Journal Article
• Authors: Matsuura, Shun; Morikawa, Keisuke; Ito, Yutaro; Kagoo, Namio; Kubota, Tsutomu; Ichijo, Koshiro; Mochizuki, Eisuke; Uehara, Masahiro; Harada, Masanori; Tsukui, Masaru; Koshimizu, Naoki
• Is Part Of: Respiratory medicine case reports. Volume 31(2020)
• Publication Date: 2020
• Subjects: EGFR -- Exon 20 insertion -- Durvalumab -- Non-small-cell lung cancer; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2020.101236
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 insertion adenocarcinoma with high-expression programmed cell death ligand 1 (PD-L1). He showed stable disease to chemoradiation treatment at the primary tumor site. However, durvalumab treatment has good response. Non-small cell lung cancer with EGFR exon 20 insertion and high PD-L1 expression may be treated with immunotherapy exposure.